| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival |
| Creator | Mansouri et al. |
| Author | Hanane Mansouri |
| Author | Lindsay B. Alcaraz |
| Author | Caroline Mollevi |
| Author | Aude Mallavialle |
| Author | William Jacot |
| Author | Florence Boissière-Michot |
| Author | Joelle Simony-Lafontaine |
| Author | Valérie Laurent-Matha |
| Author | Pascal Roger |
| Author | Emmanuelle Liaudet-Coopman |
| Author | Séverine Guiu |
| Abstract | BACKGROUND: In the triple-negative breast cancer (TNBC) group, the luminal androgen receptor subtype is characterized by expression of androgen receptor (AR) and lack of estrogen receptor and cytokeratin 5/6 expression. Cathepsin D (Cath-D) is overproduced and hypersecreted by breast cancer (BC) cells and is a poor prognostic marker. We recently showed that in TNBC, Cath-D is a potential target for antibody-based therapy. This study evaluated the frequency of AR/Cath-D co-expression and its prognostic value in a large series of patients with non-metastatic TNBC. METHODS: AR and Cath-D expression was evaluated by immunohistochemistry in 147 non-metastatic TNBC. The threshold for AR positivity (AR+) was set at ?1% of stained cells, and the threshold for Cath-D positivity (Cath-D+) was moderate/strong staining intensity. Lymphocyte density, macrophage infiltration, PD-L1 and programmed cell death (PD-1) expression were assessed. RESULTS: Scarff-Bloom-Richardson grade 1-2 and lymph node invasion were more frequent, while macrophage infiltration was less frequent in AR+/Cath-D+ tumors (62.7%). In multivariate analyses, higher tumor size, no adjuvant chemotherapy and AR/Cath-D co-expression were independent prognostic factors of worse overall survival. CONCLUSIONS: AR/Cath-D co-expression independently predicted overall survival. Patients with TNBC in which AR and Cath-D are co-expressed could be eligible for combinatory therapy with androgen antagonists and anti-Cath-D human antibodies. |
| Publication | Cancers |
| Volume | 12 |
| Issue | 5 |
| Pages | 1244 |
| Date | 2020-05-15 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers12051244 |
| ISSN | 2072-6694 |
| Library Catalog | PubMed |
| Extra | PMID: 32429078 PMCID: PMC7281089 |
| Tags | original |
| Date Added | 2023/11/14 - 15:27:28 |
| Date Modified | 2023/11/14 - 15:38:51 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
